One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.

Plaque psoriasis, a chronic autoimmune disorder that causes thick, scaly, itchy patches—the eponymous plaques—to form on the skin, affects more than 7.5 million adults in the United States.

Discover a recent study from 12 hospitals across China that has shed new light on personalised care for plaque psoriasis.

and adults with chronic moderate-to-severe plaque psoriasis. In clinical trials, the most common adverse effect of this treatment was injection site reaction (ISR). This can occur in up to 49% of ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

Alumis’ most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is currently being evaluated for the treatment of ...

Johnson & Johnson recently rolled out a TV ad that takes aim at a major disparity in dermatology: the fact that people of ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments," said Samit ...

Tremfya is approved for the treatment of adults with moderate to severe plaque psoriasis who may benefit from systemic therapy or phototherapy. Johnson & Johnson NewsMORE Related Stocks Indices ...

The study, focusing on adults with moderate plaque psoriasis and special site involvement, who had previously failed topical treatments ... color with moderate to severe scalp psoriasis and ...